RIGEL PHARMACEUTICALS, INC. — Revenue by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/0e3d0c77-3d46-49d7-86bb-8c56de06f37e/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $294.3M | 2025-01-01 – 2025-12-31 | evidence 0001034842-26-000015 |
| FY 2024 | $179.3M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-002169 |
| FY 2023 | $116.9M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-002475 |
| FY 2022 | $120.2M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-003035 |
| FY 2021 | $149.2M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-002551 |
| FY 2020 | $108.6M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-002254 |
| FY 2019 | $59.3M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-001624 |
| FY 2018 | $44.5M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-001310 |
| FY 2017 | $4.5M | 2017-01-01 – 2017-12-31 | evidence 0001558370-19-001310 |
| FY 2016 | $20.4M | 2016-01-01 – 2016-12-31 | evidence 0001558370-19-001310 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
RIGEL PHARMACEUTICALS, INC. — all facts · Net Income · Operating Income